Phase 2 dabogratinib data readout call announcement drives TYRA surge

 

Phase 2 dabogratinib data readout call announcement drives 16.5% TYRA surge

• Tyra announced it will host a Sept 9 conference call to discuss initial SURF302 Phase 2 results for oral dabogratinib in FGFR3-altered IR NMIBC.
• Data will cover safety from >40 patients and efficacy from >20 patients across two dose levels, per Q2 update.
• Builds directly on Aug 4 earnings guidance for September readout with strong enrollment progress reported.
• Dabogratinib is lead FGFR3 inhibitor under '3x3' strategy targeting multiple high-value indications including bladder cancers.
• Biotech traders piled in ahead of the imminent readout, viewing it as key de-risking event for potential first-in-class therapy.

https://finviz.com/stock?t=TYRA&p=d